Finance Shopping Travel Webhosting Business Webmaster Hotels More

Keyword links
Business
Dating
Diets
Digital camera
Divx movies
Education
Fishing
Fonts
Health
Jobs
Kids
Movies

Real estate
Shopping
Skiing
Sports
Supplements
Telecom
Translators

Computer
Computer
Flightsimulator
Games
Memory
Monitors
Motherboards
Notebooks
Pda
Printers
Processors
Scanners

Security
Software
Toner

Finance
Accountants
Consultants
Commodities
Debt
Day trading
Earn money
Insurance
Investment guide
Leasing
Loans
Mortgage
Mutual funds
Offshore
Real estate
Stock and bonds
Venture capital


Travel
Airlines
Airports
Cruises
Hotels
Restaurants
Scuba diving

Asia
Africa
Caribbean
Central America
Europe
Middle East
North America
South America
Oceania

Webmaster
Domain names
Ecommerce
Free resources
Shoppingcarts
Webdesign
Webhosting


More topics.....


logo.jpg (25250 bytes)

Nymox Files Premarket Approval Application with FDA for Alzheimer Urine Test


Google
  Web www.ugamedia.com

MAYWOOD, NJ (February 2004) Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that it has filed a Premarket Approval application (PMA) with the FDA for the Company's Alzheimer urine test (AlzheimAlert™).

AlzheimAlert™ is a non-invasive urine test intended to help physicians in the diagnosis of Alzheimer's disease. The AlzheimAlert™ test measures the level of a brain protein called neural thread protein (NTP) known to be elevated in the urine of patients with Alzheimer's disease. There is an extensive scientific and medical literature on neural thread protein and its relationship to Alzheimer's disease and on the clinical accuracy and utility of AlzheimAlert™. Publications include, for example, Alzheimer's Reports (2002; 1: 1-6); Neurology & Clinical Neurophysiology (2002; 1: 2-7); Frontiers in Bioscience (2002; 7:d989-96); Cellular and Molecular Life Sciences (2001; 58: 844-849); Journal of Alzheimer's Disease (2001; 3: 345-353); Journal of Neuropathology and Experimental Neurology (2001; 60: 195-207) and (1996; 55: 1038-1050); Neurology (2000; 55: 1068) and (2000; 54: 1498-1504); Alzheimer's Reports (2001; 4: 61-65), (2000; 3: 177-184) and (1999; 2: 327-332); Journal of Clinical Laboratory Analysis (1998; 12: 285-288) and (1998; 12: 223-226); Journal of Contemporary Neurology (1998; 4A: 2-6); and Journal of Clinical Investigation (1997; 100: 3093-3104).

The Company is also developing new generation drugs that target NTP, which plays an important role in the Alzheimer's disease process.

More information about Nymox is available at www.nymox.com


Google
  Web www.ugamedia.com

Post your press release here (free of charge)

 

Subscribe to international news by email

Email address: 
Click here for information